世界の黄斑変性症(AMD)・その他網膜疾患治療薬市場2021-2031

【英語タイトル】Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2021-2031

visiongainが出版した調査資料(VGA21MA030)・商品コード:VGA21MA030
・発行会社(調査会社):visiongain
・発行日:2021年2月
・ページ数:445
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名様閲覧用、1年間、印刷不可)USD5,199 ⇒換算¥769,452見積依頼/購入/質問フォーム
Global Site License(法人閲覧用、1年間、印刷可)USD9,099 ⇒換算¥1,346,652見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

本調査レポートでは、世界の黄斑変性症(AMD)・その他網膜疾患治療薬の市場について調査・分析し、レポート概要、エグゼクティブサマリー、市場動向、新型コロナウイルス感染症の影響、AMD・その他疾患用医薬品、AMD・その他疾患治療薬の疾患別(AMD、糖尿病性黄斑浮腫、糖尿病性網膜症、網膜静脈閉塞症、その他網膜疾患)分析、AMD・その他疾患治療薬の製品別(ルセンティス、アイリーア、アバスチン、ビスダイン(バリアント/ノバルティス)、その他医薬品)分析、流通チャネル別(病院薬局、小売薬局、その他)分析、地域別分析、企業情報などの項目を掲載しています。
・レポート概要
・エグゼクティブサマリー
・市場動向
・新型コロナウイルス感染症の影響
・黄斑変性症(AMD)・その他疾患用医薬品
・世界の黄斑変性症(AMD)・その他疾患治療薬市場規模:疾患別(AMD、糖尿病性黄斑浮腫、糖尿病性網膜症、網膜静脈閉塞症、その他網膜疾患)
・世界の黄斑変性症(AMD)・その他疾患治療薬市場規模:製品別(ルセンティス、アイリーア、アバスチン、ビスダイン(バリアント/ノバルティス)、その他医薬品)
・世界の黄斑変性症(AMD)・その他網膜疾患治療薬市場規模:流通チャネル別(病院薬局、小売薬局、その他)
・世界の黄斑変性症(AMD)・その他網膜疾患治療薬市場規模:地域別
・企業情報

The global AMD and other retinal disease drugs market accounted for US$xx billion in 2020 and is expected to grow at a CAGR of xx% during the forecast period to reach US$xx billion by 2031. Growing investment in drug R&D by pharmaceutical and biopharmaceutical companies, rising prevalence of retinal diseases, mounting demand for biologics & biosimilars, and developing healthcare infrastructure in emerging economies are some of the major factors that propel the market growth.

Age-related macular degeneration accounts for 8.7% of all blindness worldwide and is the most common cause of blindness in developed countries particularly in people older than 60 years. The prevalence of AMD is likely to increase as a consequence of exponential population ageing.

There have been significant advances in the management of wet age-related macular degeneration with the introduction of anti-angiogenesis therapy, and patients now have effective treatment options that can prevent blindness and, in many cases, restore vision. However, these treatments are expensive and not available to all patients in many countries. The report explains that growth in the market will be driven by the entry of longer-acting anti-angiogenic therapies and the launch of products for dry AMD and geographic atrophy (GA), which are two forms of advanced disease for which there are no approved therapies. Thus, understanding the burden, population impact and treatments options is essential to develop strategies for adequate health care planning and delivery, which require both precise and modern market estimates.

How this report will benefit you

The report provides a thoughtful understanding into the global age-related macular degeneration market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, PEST analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the macular degeneration industry in any manner.

As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

In this brand-new 445-page report you will receive 279 charts– all unavailable elsewhere.

The 445-page Visiongain report provides clear detailed insight into the macular degeneration market. Discover the key trends and development in the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
• Global macular degeneration and other retinal diseases drug market forecasts from 2021-2031
• This report also breaks down the revenue forecast to 2031 for the global macular degeneration and other retinal diseases drug market by indication, type, product and distribution channel:
• By Indication
• Diabetic Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Others
• By Type
• Wet AMD
• Dry AMD
• Geographic Atrophy
• By Product
• Lucentis
• Eylea
• Avastin
• Visudyne
• Others
• By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Others
This report discusses the market trends and developments of each submarket.

Need industry data? Please contact us today.
• Our study discusses the selected leading companies that are the major players in the macular degeneration (AMD) and other retinal diseases drugs market:
• Novartis AG
• F. Hoffmann-La Roche, Ltd.
• GlaxoSmithKline Pharmaceuticals Ltd.
• Bayer AG
• Pfizer Inc.
• Regeneron Pharmaceuticals
• Bausch & Lomb Incorporated
• Apellis Pharmaceuticals
• Santen Pharmaceuticals
• Alimera Sciences
• AbbVie Inc.
• IVERIC bio, Inc. (Formerly Ophthotech)
• Graybug Vision, Inc.
• Kubota Vision Inc.
Visiongain’s study is intended for anyone requiring commercial analyses for the global macular degeneration (AMD) and other retinal diseases drugs market. You find data, trends and predictions.

❖ レポートの目次 ❖

1. Report Overview
1.1 Introduction to Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market
1.1.1 What are Retinal Diseases?
1.1.2 Types of Retinal Diseases
1.1.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
1.1.4 Nearly 200 Million People with AMD?
1.1.5 Over 100 Million with DR
1.1.6 First RVO Estimates Suggest Patient Population of 16 Million
1.2 Why You Should Read This Report
1.3 What This Report Delivers
1.4 Key Questions Answered By This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.6.3 Market Evaluation & Forecast Methodology
1.7 Frequently Asked Questions (FAQs)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2 Executive Summary
3 Market Dynamics
3.1 Drivers
3.1.1 Rise in Incidence of Retinal Disorders
3.1.2 Upsurge in Geriatric Population
3.2 Restraints
3.2.1 Increasing Use of Generic Drugs
3.2.2 Lack of Awareness regarding AMD
3.2.3 Stringent FDA Regulations
3.3 Opportunities
3.3.1 Growing Demand for Cutting-edge Therapeutic Treatments for Retinal Diseases to Aid Market
3.3.2 Untapped Opportunities for the Dry-AMD Treatment
3.4 Trends
3.4.1 Mergers, Agreements, and Acquisitions By The Market Players
3.4.2 New Product Launches to Drive Market
3.5 SWOT Analysis
3.5.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
3.5.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
3.5.3 Opportunities: New Markets and R&D Synergies
3.5.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
3.6 Porter’s Five Forces Analysis
3.6.1 Bargaining Power of Supplier: Moderate
3.6.2 Bargaining Power of Buyer: Moderate
3.6.3 Competitive Rivalry: High
3.6.4 Threat of New Entrants: Moderate
3.6.5 Threat of Substitutes: Moderate
3.7 PEST Analysis
3.7.1 Political Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: The Demography and Diabetes Challenges
3.7.2 Economic Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: Off-Label Treatment and Reimbursement Issues
3.7.3 Social Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: Low Diagnosis, Low Compliance
3.7.4 Technological Factors Impacting Global AMD and Other Retinal Diseases Drugs Market: Innovation for the Eye
4 COVID-19 Impact: Global AMD and Other Disease Drugs Market
4.1.1 “V” shaped Recovery – Rapid Decline – Sharp Borrow -Rapid Recovery
4.1.2 “U” Shaped Recovery -Rapid Decline Early Then Slow – Gradual at the Bottom – Slow Recovery at First – Faster Recovery Later On
4.1.3 “W” Shaped Recovery -Rapid Decline – Rapid Recovery- Return of Virus – Another Sharp Decline -Recovery
4.1.4 “L” Shaped Recovery – Rapid Decline – Then Slow Growth
5 World AMD and Other Disease Drugs Market, 2020
5.1 Market to Grow Rapidly by 2031
5.2 Eylea Became Leading Drug in the Market
5.3 Regeneron is the Leading Player in the Retinal Drug Market
6 AMD and Other Disease Drugs Market by Indication Forecast, 2021-2031
6.1 AMD Segment Market Forecast, 2021-2031
6.1.1 Largest Revenue-Grossing Segment
6.1.2 Recovery Scenarios (V, U, W, L)
6.1.3 Wet AMD Segment Market Forecast, 2021-2031
6.1.3.1 Wet AMD Angiogenic Processes Offer Well-Defined Drug Targets
6.1.3.2 Wet AMD Segment Market Forecast, 2021-2031
6.1.3.3 Recovery Scenarios (V, U, W, L)
6.1.4 Dry AMD Segment Market Forecast, 2021-2031
6.1.4.1 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
6.1.4.2 Revenue Forecast for Wet AMD segment, 2020-2031
6.1.4.3 Recovery Scenarios (V, U, W, L)
6.1.5 Geographic Atrophy Segment Market Forecast, 2021-2031
6.1.5.1 Geographic Atrophy: Unmet Need to Arrest or Reverse Damage to RPE
6.1.5.2 Revenue Forecast for Geographic Atrophy segment, 2020-2031
6.1.5.3 Recovery Scenarios (V, U, W, L)
6.2 Diabetic Macular Edema Market Forecast, 2021-2031
6.2.1 Fast Growing Segment
6.2.2 Revenue Forecast for Diabetic Macular Edema segment, 2020-2031
6.2.3 Recovery Scenarios (V, U, W, L)
6.3 Diabetic Retinopathy Market Forecast, 2021-2031
6.3.1 Diabetic Retinopathy: Coming into Clinical Focus, with DME the Main Target
6.3.2 Segment to Grow in Importance as Diabetes Epidemic Continues
6.3.3 Recovery Scenarios (V, U, W, L)
6.4 Retinal Vein Occlusion Market Forecast, 2021-2031
6.4.1 Retinal Vein Occlusion Is The Second Most Common Vascular Disease Of The Retina
6.4.2 Recovery Scenarios (V, U, W, L)
6.5 Other Retinal Diseases Market Forecast, 2021-2031
6.5.1 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
6.5.2 Recovery Scenarios (V, U, W, L)
7 AMD and Other Disease Drugs Market by Product Forecast, 2021-2031
7.1 Will the Current Products Dominate the Market through 2031?
7.2 Lucentis: Second Leading Drug in the Market
7.2.1 Recovery Scenarios (V, U, W, L)
7.2.2 Shadow of Avastin Still Hangs Over Lucentis
7.2.3 Lucentis/Avastin Matters
7.2.4 Eylea: The Bigger Threat to Lucentis?
7.2.5 Extending the Label, Widening the Battleground: Lucentis Moves into DME and Beyond
7.2.6 Improving Cost and Compliance for Lucentis
7.2.7 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
7.3 Eylea: Holds the Throne?
7.3.1 Increasing Revenue Growth in Past: Outside the US Sale Amplified
7.3.2 Recovery Scenarios (V, U, W, L)
7.3.3 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
7.3.4 First Wave of Eylea’s Expansion Finally Beginning to Break?
7.3.5 Eylea into DME and Other New Indications
7.3.6 How Far Can Eylea’s Momentum Carry It?
7.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
7.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
7.4.2 Recovery Scenarios (V, U, W, L)
7.4.3 Judicial Review Averted in the UK by Price Adjustment
7.4.4 Multiple Attempts to Block Off-Label Avastin Since 2007
7.4.5 Roche and Novartis Challenge CATTs Headline Conclusions
7.4.6 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
7.4.7 Will Anything Dislodge Avastin from its Central Position?
7.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
7.5.1 Visudyne Revenue Forecast, 2021-2031
7.5.2 Recovery Scenarios (V, U, W, L)
7.6 Other Drugs for Macular Degeneration and Other Retinal Diseases
7.6.1 Other Drugs Revenue Forecast, 2021-2031
7.6.2 Recovery Scenarios (V, U, W, L)
8 Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Distribution Channel Forecast, 2021-2031
8.1 Hospital Pharmacy Segment Market Forecast, 2021-2031
8.1.1 Largest Revenue Generating Segment
8.1.2 Recovery Scenarios (V, U, W, L)
8.2 Retail Pharmacy Segment Market Forecast, 2021-2031
8.2.1 Fastest Growing Segment in the Market
8.2.2 Recovery Scenarios (V, U, W, L)
8.3 Others Segment Market Forecast, 2021-2031
8.3.1 Developing Healthcare Infrastructure Is Expected To Drive The Market Growth
8.3.2 Recovery Scenarios (V, U, W, L)
9 Wet AMD Segment: Pipeline Analysis
9.1 The Leading Pipeline Candidates
9.2 Eylea® (aflibercept)
9.3 Brolucizumab (Novartis)
9.4 KSI-301
9.5 OPT-302
9.6 GB-102
9.7 Combination of Drugs for the Treatment of AMD and Other Retinal Diseases
9.7.1 Anti-VEGF and Cosopt (Dorzolamide-timolol) Drugs
9.7.2 REGN 910-3 and RG7716
9.7.3 Anti-VEGF and OPT-302 Drugs
9.7.4 Others Combination Therapy Developments
10 Pipeline for Dry AMD Segment
10.1 Apl-2
10.2 Zimura
10.3 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
10.4 Neuroprotection: One of Modern Medicine’s Holy Grails
10.5 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
10.6 Elamipretide
10.7 Subthreshold Nanosecond Laser
10.8 Lampalizumab
11 Pipeline for Diabetic Retinopathy Segment
11.1 Steroids in Development for DR
11.2 APX3330
12 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
12.1 Global Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Region Forecast 2021-2031
12.2 Recovery Scenarios (V, U, W, L)
12.3 Epidemiology of Global Age-Related Macular Degeneration in Nine Major Pharmaceutical Markets
13 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
13.1 North America is The Largest Revenue Grossing Region in the Global Market
13.2 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
13.3 Recovery Scenarios (V, U, W, L)
13.4 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
13.5 North America Macular Degeneration (AMD) Drugs Market Forecast by Type
13.6 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
13.7 North America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
13.8 U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
13.8.1 Rise In The Number Of Drug Approvals
13.8.2 Presence of Highly Developed Healthcare Infrastructure
13.8.3 Recovery Scenarios (V, U, W, L): U.S. Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
13.9 Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
13.9.1 Anticipated To Witness The Fastest Growth In The North America Region
13.9.2 Benefits Of Manufacturing And R&D Operations In Canada
13.9.3 Recovery Scenarios (V, U, W, L): Canada Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
14.1 Second Largest Market in the Global Market
14.2 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
14.3 Recovery Scenarios (V, U, W, L)
14.4 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
14.5 Europe Macular Degeneration (AMD) Drugs Market Forecast by Type
14.6 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
14.7 Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
14.8 Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.8.1 Growing Geriatric Population In This Region Is Expected To Boost The Regional Market Growth
14.8.2 One Of The Oldest Universal Health Systems Within Europe
14.8.3 Recovery Scenarios (V, U, W, L): Germany Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.9 UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.9.1 Presence Of Well-Developed R&D Infrastructure
14.9.2 Increasing Prevalence Of Retinal Diseases In This Region
14.9.3 Recovery Scenarios (V, U, W, L): UK Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.10 France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.10.1 Growing Demand For Affordable Healthcare Services
14.10.2 Growing Demand For Innovative Medicine And Pharmaceutical
14.10.3 Recovery Scenarios (V, U, W, L): France Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.11 Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.11.1 Pharmaceutical Manufacturing Hub
14.11.2 Growing Demand For Advanced Therapies For The Treatment Of Retinal Diseases
14.11.3 Recovery Scenarios (V, U, W, L): Italy Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.12 Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.12.1 Spanish Economy Is Growing Strong
14.12.2 Demand For Drugs Is Influenced By The Growth Of The Pharmaceutical Industry
14.12.3 Recovery Scenarios (V, U, W, L): Spain Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.13 Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.13.1 Unmet Pharmaceutical Needs
14.13.2 Government Support For Development of the Healthcare Infrastructure
14.13.3 Recovery Scenarios (V, U, W, L): Russia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.14 Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
14.14.1 Increasing Prevalence Of Retinal Diseases
14.14.2 Recovery Scenarios (V, U, W, L): Rest of Europe Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
15.1 Asia Pacific is the Fastest Growing Market
15.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
15.3 Recovery Scenarios (V, U, W, L)
15.4 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
15.5 Asia Pacific Macular Degeneration (AMD) Drugs Market Forecast by Type
15.6 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
15.7 Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
15.8 Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.8.1 Japan Accounted For The Largest Market Share In The Asia Pacific Region
15.8.2 Japan Spent A High Amount On Healthcare
15.8.3 Recovery Scenarios (V, U, W, L): Japan Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.9 China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.9.1 Presence Of Large Geriatric Population
15.9.2 Increasing Healthcare Spending In China
15.9.3 Recovery Scenarios (V, U, W, L): China Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.10 India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.10.1 Developing Healthcare Infrastructure
15.10.2 Increasing Prevalence Of Retinal Diseases
15.10.3 Recovery Scenarios (V, U, W, L): India Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.11 Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.11.1 Government Programs To Expand Access To Quality Eye Care Facilities
15.11.2 Well Established Healthcare Infrastructure
15.11.3 Recovery Scenarios (V, U, W, L): Australia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.12 South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.12.1 Growing Healthcare Awareness Among People
15.12.2 Increasing Prevalence Of Retinal Diseases
15.12.3 Recovery Scenarios (V, U, W, L): South Korea Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.13 Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
15.13.1 Rising Disposable Income
15.13.2 Recovery Scenarios (V, U, W, L): Rest of Asia Pacific Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
16.1 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market
16.2 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
16.3 Recovery Scenarios (V, U, W, L)
16.4 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
16.5 Latin America Macular Degeneration (AMD) Drugs Market Forecast by Type
16.6 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
16.7 Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
16.8 Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.8.1 Fastest Growing Economies in Latin America
16.8.2 Government Incentives to Keep Manufacturing Local
16.8.3 Recovery Scenarios (V, U, W, L): Brazil Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.9 Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.9.1 Lower Manufacturing Costs Than In The US
16.9.2 R&D And Drug Approval Process in Mexico Has Several Advantages
16.9.3 Recovery Scenarios (V, U, W, L): Mexico Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.10 Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.10.1 Boom in Pharmaceutical Industry
16.10.2 Adoption Of AMD And Other Retinal Diseases Drugs For The Treatment Of Retinal Diseases
16.10.3 Recovery Scenarios (V, U, W, L): Argentina Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.11 Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
16.11.1 Developing Healthcare Infrastructure
16.11.2 Recovery Scenarios (V, U, W, L): Rest of Latin America Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market, 2021-2031
17.1 Rising Prevalence of Chronic Retinal Diseases
17.2 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market by Country, Forecast 2021-2031
17.3 Recovery Scenarios (V, U, W, L)
17.4 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Indication
17.5 MEA Macular Degeneration (AMD) Drugs Market Forecast by Type
17.6 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Product
17.7 MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast by Distribution Channel
17.8 South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.8.1 Increasing Focus Of Pharmaceutical & Pharmaceutical Companies In This Region
17.8.2 Supportive Government Initiatives
17.8.3 Recovery Scenarios (V, U, W, L): South Africa Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.9 Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.9.1 Presence Of Huge Growth Opportunities
17.9.2 Rising Prevalence Of The Diseases
17.9.3 Recovery Scenarios (V, U, W, L): Saudi Arabia Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.10 Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
17.10.1 Strong Presence Of Leading Companies
17.10.2 Growing Prevalence of Retinal Diseases
17.10.3 Recovery Scenarios (V, U, W, L): Rest of MEA Macular Degeneration (AMD) and Other Retinal Disease Drugs Market Forecast, 2021-2031
18 Company Profiles
18.1 Company Share Analysis
18.2 Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Recent Developments, 2017-2020
18.3 Novartis AG
18.3.1 Company Snapshot
18.3.2 Company Overview
18.3.3 Financial Analysis
18.3.3.1 Net Revenue, 2015-2019
18.3.3.2 Product Revenue Shares, 2019
18.3.3.3 Novartis Pharmaceuticals Business Unit Revenue Shares, 2019
18.3.3.4 Regional Revenue Shares, 2019
18.3.4 Product Benchmarking
18.3.5 Recent Developments, 2017-2020
18.4 F. Hoffmann-La Roche, Ltd.
18.4.1 Company Snapshot
18.4.2 Company Overview
18.4.3 Financial Analysis
18.4.3.1 Net Revenue, 2015-2019
18.4.3.2 Product Revenue Shares, 2019
18.4.3.3 Pharmaceuticals Business Revenue Shares, 2019
18.4.3.4 Regional Revenue Shares, 2019
18.4.4 Product Benchmarking
18.4.5 Recent Developments, 2017-2020
18.5 GlaxoSmithKline Pharmaceuticals Ltd.
18.5.1 Company Snapshot
18.5.2 Company Overview
18.5.3 Financial Analysis
18.5.3.1 Net Revenue, 2015-2019
18.5.3.2 Product Revenue Shares, 2019
18.5.3.3 Pharmaceuticals Segment Revenue Shares, 2019
18.5.3.4 Regional Revenue Shares, 2019
18.5.4 Product Benchmarking
18.5.5 Recent Developments, 2017-2020
18.6 Bayer AG
18.6.1 Company Snapshot
18.6.2 Company Overview
18.6.3 Financial Analysis
18.6.3.1 Net Revenue, 2015-2019
18.6.3.2 Product Revenue Shares, 2019
18.6.3.3 Regional Revenue Shares, 2019
18.6.4 Product Benchmarking
18.6.5 Recent Developments, 2017-2020
18.7 Pfizer Inc.
18.7.1 Company Snapshot
18.7.2 Company Overview
18.7.3 Financial Analysis
18.7.3.1 Net Revenue, 2015-2019
18.7.3.2 Product Revenue Shares, 2019
18.7.3.3 Regional Revenue Shares, 2019
18.7.4 Product Benchmarking
18.7.5 Recent Developments, 2017-2020
18.8 Regeneron Pharmaceuticals
18.8.1 Company Snapshot
18.8.2 Company Overview
18.8.3 Financial Analysis
18.8.3.1 Net Revenue, 2015-2019
18.8.3.2 Product Revenue Shares, 2019
18.8.3.3 Regional Revenue Shares, 2019
18.8.4 Product Benchmarking
18.8.5 Recent Developments, 2017-2020
18.9 Bausch & Lomb Incorporated
18.9.1 Company Snapshot
18.9.2 Company Overview
18.9.3 Financial Analysis
18.9.3.1 Net Revenue, 2015-2019
18.9.3.2 Product Revenue Shares, 2019
18.9.3.3 Regional Revenue Shares, 2019
18.9.4 Product Benchmarking
18.9.5 Recent Developments, 2017-2020
18.10 Apellis Pharmaceuticals
18.10.1 Company Snapshot
18.10.2 Company Overview
18.10.3 Product Benchmarking
18.10.4 Recent Developments, 2017-2020
18.11 Santen Pharmaceuticals
18.11.1 Company Snapshot
18.11.2 Company Overview
18.11.3 Financial Analysis
18.11.3.1 Net Revenue, 2015-2019
18.11.4 Product Benchmarking
18.11.5 Recent Developments, 2017-2020
18.12 Alimera Sciences
18.12.1 Company Snapshot
18.12.2 Company Overview
18.12.3 Financial Analysis
18.12.3.1 Net Revenue, 2015-2019
18.12.3.2 Regional Revenue Shares, 2019
18.12.4 Product Benchmarking
18.12.5 Recent Developments, 2017-2020
18.13 AbbVie Inc.
18.13.1 Company Snapshot
18.13.2 Company Overview
18.13.3 Financial Analysis
18.13.3.1 Net Revenue, 2015-2019
18.13.3.2 Product Revenue Shares, 2019
18.13.3.3 Regional Revenue Shares, 2019
18.13.4 Product Benchmarking
18.13.5 Recent Developments, 2017-2020
18.14 IVERIC bio, Inc. (Formerly Ophthotech)
18.14.1 Company Snapshot
18.14.2 Company Overview
18.14.3 Product Benchmarking
18.15 Graybug Vision, Inc.
18.15.1 Company Snapshot
18.15.2 Company Overview
18.15.3 Product Benchmarking
18.16 Kubota Vision Inc.
18.16.1 Company Snapshot
18.16.2 Company Overview
18.16.3 Product Benchmarking
19 Conclusion and Recommendations
19.1 Increasing Prevalence of Retinal Disorders and Diabetes is a Major Factor Driving The Market Growth
19.2 Negative Impact of the COVID-19 Pandemic on the Market
19.3 Eylea Dominated the AMD and Other Retinal Diseases Market
19.4 Market Opportunities in the Emerging Economies



★調査レポート[世界の黄斑変性症(AMD)・その他網膜疾患治療薬市場2021-2031] (コード:VGA21MA030)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の黄斑変性症(AMD)・その他網膜疾患治療薬市場2021-2031]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆